Table 3 Distribution of the health-related characteristics and medication administered and severity and outcome in COVID-19 patients’ group (n = 140)
Health-related condition | No. (%) |
|---|---|
Chronic diseases  Diabetes mellitus  Hypertension  Ischemic Heart Disease  Chronic Kidney Disease  Chronic liver disease  Others Complaint   COPD   Cardiomyopathy   Atrial fibrillation   Mitral valve diseases   Psoriasis   Rheumatoid arthritis | 84(60.0%) |
62 (44.3%) | |
56 (40.0%) | |
12 (8.6%) | |
12 (8.6%) | |
14 (10.0%) | |
8 (5.7%) 4 (2.9%) 4 (2.9%) 2 (1.4%) 2 (1.4%) 2 (1.4%) | |
High-Resolution CT chest | Â |
 < 50% | 106 (75.7%) |
 > 50% | 34 (24.3%) |
Condition of Discharge (outcome) | Â |
 Improvement | 126 (90.0%) |
 Death | 14 (10.0%) |
Oxygen Therapy | Â |
 No | 20 (14.3%) |
 Low and high flow | 94 (67.1%) |
 CPAP | 20 (14.3%) |
 Intubation | 6 (4.3%) |
Medications | Â |
 Remdesivir | 50 (35.7%) |
 Actemra | 10 (7.1%) |
 Anticoagulants | 134 (95.7%) |
 Corticosteroids | 128 (91.4%) |
 Antibiotics | 138(98.6%) |
Severity* | Â |
 Mild | 16 (11.4%) |
 Moderate | 82 (58.6%) |
 Severe | 42 (30.0%) |